The Oncology Institute, Inc. TOI California — Deferred tax asset, valuation allowance

Other geography segments

Similar metrics at other companies

GETYUNITED STATES — Deferred tax assets, valuation allowance

$194.5M+33.3%

HLIOCA — Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance

$225K—

BLMNU.S. — Deferred tax assets, valuation allowance

$1.4M+55.6%

PRSUCA — Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance

$262.25K+195%

MATVUnited States — Valuation allowance on deferred tax assets

$81.7M+85.7%

DNOWUS And Non US — Deferred Tax Assets Valuation Allowance

$88M+319%

Questions, answered.

What is The Oncology Institute, Inc.'s california — deferred tax asset, valuation allowance?

The Oncology Institute, Inc. (TOI) reported california — deferred tax asset, valuation allowance of $16.6M in Q4 2025.

How has The Oncology Institute, Inc.'s california — deferred tax asset, valuation allowance changed year-over-year?

The Oncology Institute, Inc.'s california — deferred tax asset, valuation allowance increased by 8.6% year-over-year, from $15.29M to $16.6M.

What does california — deferred tax asset, valuation allowance mean?

This metric represents the valuation allowance established against deferred tax assets specifically attributable to the California geographic segment. It reflects management's assessment that it is more likely than not that some portion of the deferred tax assets will not be realized due to insufficient future taxable income within that jurisdiction. A change in this allowance serves as a key indicator of the company's outlook on the profitability and tax planning effectiveness of its operations in the California market.